Fremont, CA, United States of America

Xiaofeng Lu

This inventor holds 2 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignees: Novartis Ag, Novartis Vaccines & Diagnostics, Gmbh, Xoma Technology Ltd.. Active years: 2012-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xiaofeng Lu. Retrieved from https://idiyas.com/inventor/xiaofeng-lu-sj4aqvm1

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 2 

% Patents Active = 50.0



Average Co-Inventor Count = 5.3

ph-index = 2

Forward Citations = 35(Granted Patents)


Location History:

  • Albany, CA (US) (2012)
  • Fremont, CA (US) (2015)

Company Filing History:


Years Active: 2012-2015

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Xiaofeng Lu in Pharmaceutical Compositions

Introduction

Xiaofeng Lu is a notable inventor based in Fremont, CA (US). He has made significant contributions to the field of pharmaceutical compositions, particularly in the development of antagonist anti-CD40 antibodies. With a total of 2 patents, his work focuses on innovative methods for treating proliferative diseases and autoimmune conditions.

Latest Patents

Xiaofeng Lu's latest patents include groundbreaking compositions and methods. One patent details stable liquid pharmaceutical compositions comprising an antagonist anti-CD40 antibody, which serves as a therapeutically active component. These compositions are designed to maintain a pH between about 5.0 and 7.0, utilizing a buffering agent and arginine-HCl to achieve near isotonicity. This innovation is particularly useful in treating diseases with autoimmune and inflammatory components.

Another patent focuses on the therapeutic methods for diseases mediated by CD40 signaling. It involves administering a therapeutically effective amount of an antagonist anti-CD40 antibody or its antigen-binding fragment to patients. This antibody is designed to inhibit the proliferation and differentiation of human CD40-expressing cells, such as B cells, thereby providing a beneficial therapeutic effect.

Career Highlights

Throughout his career, Xiaofeng Lu has worked with prominent companies in the pharmaceutical industry, including Novartis Vaccines & Diagnostics and Novartis AG. His experience in these organizations has contributed to his expertise in developing innovative therapeutic solutions.

Collaborations

Xiaofeng Lu has collaborated with notable colleagues, including Bao-lu Chen and Li Long. These partnerships have likely enhanced his research and development efforts in the field of pharmaceutical innovations.

Conclusion

Xiaofeng Lu's contributions to the field of pharmaceutical compositions, particularly through his patents on antagonist anti-CD40 antibodies, demonstrate his commitment to advancing medical treatments. His work continues to impact the development of therapies for complex diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…